Abstract: The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG. The invention also pertains to methods for detecting IgA.
Abstract: DNA sequences encoding a novel intercellular adhesion molecule polypeptide (designated "ICAM-4") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 30, 1997
Assignee:
ICOS Corporation
Inventors:
Patrick D. Kilgannon, W. Michael Gallatin
Abstract: The present invention relates to new nucleotide sequences coding for variable regions of .beta. chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.
Abstract: DNA sequences encoding a novel intercellular adhesion molecule polypeptide (designated "ICAM-4") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures.
Type:
Grant
Filed:
May 18, 1994
Date of Patent:
December 23, 1997
Assignee:
ICOS Corporation
Inventors:
Patrick D. Kilgannon, W. Michael Gallatin
Abstract: Methods and compositions for treating bladder cancer using TGF-alpha or EGF fused to PE.sub.40 or cysteine modified derivatives are taught. Also, a method of producing TGF-alpha-PE.sub.40 derivatives of enhanced potency is described.
Type:
Grant
Filed:
April 11, 1994
Date of Patent:
November 25, 1997
Assignee:
Merck & Co., Inc.
Inventors:
David C. Heimbrook, Allen I. Oliff, Steven M. Stirdivant, Janet Ahern
Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
Type:
Grant
Filed:
July 25, 1994
Date of Patent:
November 11, 1997
Assignee:
The Beth Israel Hospital Association
Inventors:
Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier
Abstract: The present invention relates to novel chimeric proteins comprising a first polypeptide which inhibits complement activation, linked to a second polypeptide which inhibits complement activation, nucleic acids encoding novel chimeric proteins and methods of reducing inflammation with the administration of the chimeric proteins of the invention.
Abstract: Novel peptides are described which are biologically active derivatives of the EGF-like domain of NDF/heregulins and which stimulate the proliferation and differentiation of colon epithelial cells and support the survival and growth of Schwann cells.
Type:
Grant
Filed:
April 6, 1995
Date of Patent:
September 23, 1997
Assignee:
Amgen Inc.
Inventors:
Josette Francoise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
Abstract: Polynucleotide sequences encoding novel cadherin-related polypeptides, designated protocadherins, and variants thereof are provided by the invention as well as methods and materials for the recombinant production of the same. Antibody substances specific for protocadherins are also disclosed as useful for modulating the natural binding and/or regulatory activities of the protocadherins.
Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.
Abstract: .beta..sub.3 integrin subunit specific polypeptides, cDNAs which encode these polypeptides and methods of producing these polypeptides are provided.
Type:
Grant
Filed:
February 2, 1996
Date of Patent:
August 26, 1997
Assignees:
Trustees of the University of Pennsylvania, Scripps Research Institute
Inventors:
Sanford Shattil, Timothy O'Toole, Mark Ginsberg
Abstract: Pharmaceutical compositions containing safe and effective amounts of Annexin I or 33 kDa(PLBP) can be used in a number of methods for the benefit of animals.
Abstract: The present invention provides compositions and methods for promoting cell migration and tissue regeneration. The composition contains a ligand for the .alpha..sub.v .beta..sub.3 integrin and a ligand for the insulin receptor, the PDGF receptor, the IL-4 receptor, or the IGF receptor, combined in a matrix. The combination of .alpha..sub.v .beta..sub.3 ligand and growth factor produces an unexpected synergistic effect in enhancing wound healing compared with the effect of each component separately. The present invention also provides a method of wound healing and a method of inducing tissue regeneration by applying the compositions of the present invention to the site of the wound.
Abstract: The invention relates to glycoprotein ligands of selectins. The invention further relates to methods and means for preparing and to nucleic acids encoding these ligands. The invention further concerns a method of treating a symptom or condition associated with excessive binding of circulating leukocytes to endothelial cells by administering to a patient in need of such treatment a glycoprotein ligand of a selectin.
Type:
Grant
Filed:
August 23, 1994
Date of Patent:
July 29, 1997
Assignees:
Genentech, Inc., The Regents of the University of California
Inventors:
Laurence A. Lasky, Yasuyuki Imai, Steven D. Rosen, Mark S. Singer
Abstract: A soluble T-cell receptor .alpha.-chain produced by suppressor T-cell. The said soluble T-cell receptor .alpha.-chain is useful as a prophylactic and therapeutic agent for autoimmune diseases generated to a wide variety of autoantigens irrespective of specificity to the said suppressor T-cell.
Abstract: The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG.
Abstract: A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps. The growth factors may be useful in the promotion of angiogenesis, such as in the promotion of wound healing, bone healing and in the treatment of burns, as well as in promoting the formation, maintenance and repair of tissue, in particular, neural tissue.
Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
Type:
Grant
Filed:
May 8, 1995
Date of Patent:
June 10, 1997
Assignee:
The Beth Israel Hospital Association
Inventors:
Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier
Abstract: Disclosed is a human TGF.alpha.-H1 polypeptide and DNA (RNA) encoding such TGF.alpha.-H1 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and for producing antibodies and antagonists against such polypeptide. Such polypeptides may be combined with a suitable pharmaceutical carrier or diluent to provide diagnostic, therapeutic and/or prophylactic effects against various diseases. Also provided, are methods of using the antibodies and antagonists to inhibit TGF.alpha.-H1 for therapeutic purposes.
Type:
Grant
Filed:
March 8, 1994
Date of Patent:
May 27, 1997
Assignee:
Human Genome Sciences, Inc.
Inventors:
Paul S. Meissner, Rebecca A. Fuldner, Mark D. Adams